Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

None of low 25(OH)D, high 25(OH)D, or deseasonalized (continuous) 25(OH)D concentration were significant predictors of progression to clinically definite multiple sclerosis, and none were retained in the predictive model.

Source: Progression to clinically definite multiple sclerosis according to demographic and environmental factors. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The Ausimmune Study was a population-based multi-centre incident case: control study designed to capture all incident first demyelinating event cases in four regions of Australia of differing latitude: Brisbane city (latitude 27°S), Newcastle city and surrounds (33°S), Geelong city and the Western Districts of Victoria (37°S) and the island of Tasmania (43°S).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis

Case-control study · Brain Communications · 2022

Original publication title

Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis

Caron Chapman; Robyn M Lucas; Anne-Louise Ponsonby; Bruce Taylor; Ausimmune Investigator Group ChapmanCaronDrCoulthardAlanProfDearKeithProfDwyerTerryProfKilpatrickTrevorProfLucasRobynProfMcMichaelTonyProfPenderMichaelProfPonsonbyAnne-LouiseProfTaylorBruceProfValeryPatricia CProfvan der MeiIngridA/ProfWilliamsDavidDr

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Understanding the predictors of progression from a first to a second demyelinating event (and formerly, a diagnosis of clinically definite multiple sclerosis) is important clinically. Previous studies have focused on predictors within a single domain, e.g. radiological, lacking prospective data across multiple domains. We tested a comprehensive set of personal, environmental, neurological, MRI and genetic characteristics, considered together, as predictors of progression from a first demyelinating event to clinically definite multiple sclerosis. Participants were aged 18 to 59 years and had a first demyelinating event during the study recruitment period (1 November 2003 to 31 December 2006) for the Ausimmune Study (n = 216) and had follow-up data to 2 to 3 years post-initial interview.

Detailed baseline data were available on a broad range of demographic and environmental factors, MRI, and genetic and viral studies. Follow-up data included confirmation of clinically definite multiple sclerosis (or not) and changes in environmental exposures during the follow-up period. We used multivariable logistic regression and Cox proportional hazards regression modelling to test predictors of, and time to, conversion to clinically definite multiple sclerosis. On review, one participant had an undiagnosed event prior to study recruitment and was excluded (n = 215).

Data on progression to clinically definite multiple sclerosis were available for 91.2% (n = 196); 77% were diagnosed as clinically definite multiple sclerosis at follow-up. Mean (standard deviation) duration of follow-up was 2.7 (0.7) years. The set of predictors retained in the best predictive model for progression from a first demyelinating event to clinically definite multiple sclerosis were as follows: younger age at first demyelinating event [adjusted odds ratio (aOR) = 0.92, 95% confidence interval (CI) = 0.87 to 0.97, per additional year of age); being a smoker at baseline (versus not) (aOR = 2.55, 95% CI 0.85 to 7.69); lower sun exposure at age 6 to 18 years (aOR = 0.86, 95% CI 0.74 to 1.00, per 100 kJ/m2 increment in ultraviolet radiation dose), presence (versus absence) of infratentorial lesions on baseline magnetic resonance imaging (aOR = 7.41, 95% CI 2.08 to 26.41); and single nucleotide polymorphisms in human leukocyte antigen (HLA)-B (rs2523393, aOR = 0.25, 95% CI 0.09 to 0.68, for any G versus A:A), TNFRSF1A (rs1800693, aOR = 5.82, 95% CI 2.10 to 16.12, for any C versus T:T), and a vitamin D-binding protein gene (rs7041, aOR = 3.76, 95% CI 1.41 to 9.99, for any A versus C:C).

The final model explained 36% of the variance. Predictors of more rapid progression to clinically definite multiple sclerosis (Cox proportional hazards regression) were similar. Genetic and magnetic resonance imaging characteristics as well as demographic and environmental factors predicted progression, and more rapid progression, from a first demyelinating event to a second event and clinically definite multiple sclerosis.

Chapman et al. report that in a cohort of people with a first demyelinating event, younger age, smoking, low sun exposure, infratentorial lesions on MRI, and genes in HLA, vitamin D-binding protein, and tumour necrosis factor receptor 1A predicted faster progression to clinically definite multiple sclerosis over 2 to 3 years.

Authors’ abstract

Abstract

Understanding the predictors of progression from a first to a second demyelinating event (and formerly, a diagnosis of clinically definite multiple sclerosis) is important clinically. Previous studies have focused on predictors within a single domain, e.g. radiological, lacking prospective data across multiple domains. We tested a comprehensive set of personal, environmental, neurological, MRI and genetic characteristics, considered together, as predictors of progression from a first demyelinating event to clinically definite multiple sclerosis. Participants were aged 18 to 59 years and had a first demyelinating event during the study recruitment period (1 November 2003 to 31 December 2006) for the Ausimmune Study (n = 216) and had follow-up data to 2 to 3 years post-initial interview.

Detailed baseline data were available on a broad range of demographic and environmental factors, MRI, and genetic and viral studies. Follow-up data included confirmation of clinically definite multiple sclerosis (or not) and changes in environmental exposures during the follow-up period. We used multivariable logistic regression and Cox proportional hazards regression modelling to test predictors of, and time to, conversion to clinically definite multiple sclerosis. On review, one participant had an undiagnosed event prior to study recruitment and was excluded (n = 215).

Data on progression to clinically definite multiple sclerosis were available for 91.2% (n = 196); 77% were diagnosed as clinically definite multiple sclerosis at follow-up. Mean (standard deviation) duration of follow-up was 2.7 (0.7) years. The set of predictors retained in the best predictive model for progression from a first demyelinating event to clinically definite multiple sclerosis were as follows: younger age at first demyelinating event [adjusted odds ratio (aOR) = 0.92, 95% confidence interval (CI) = 0.87 to 0.97, per additional year of age); being a smoker at baseline (versus not) (aOR = 2.55, 95% CI 0.85 to 7.69); lower sun exposure at age 6 to 18 years (aOR = 0.86, 95% CI 0.74 to 1.00, per 100 kJ/m2 increment in ultraviolet radiation dose), presence (versus absence) of infratentorial lesions on baseline magnetic resonance imaging (aOR = 7.41, 95% CI 2.08 to 26.41); and single nucleotide polymorphisms in human leukocyte antigen (HLA)-B (rs2523393, aOR = 0.25, 95% CI 0.09 to 0.68, for any G versus A:A), TNFRSF1A (rs1800693, aOR = 5.82, 95% CI 2.10 to 16.12, for any C versus T:T), and a vitamin D-binding protein gene (rs7041, aOR = 3.76, 95% CI 1.41 to 9.99, for any A versus C:C).

The final model explained 36% of the variance. Predictors of more rapid progression to clinically definite multiple sclerosis (Cox proportional hazards regression) were similar. Genetic and magnetic resonance imaging characteristics as well as demographic and environmental factors predicted progression, and more rapid progression, from a first demyelinating event to a second event and clinically definite multiple sclerosis.

Chapman et al. report that in a cohort of people with a first demyelinating event, younger age, smoking, low sun exposure, infratentorial lesions on MRI, and genes in HLA, vitamin D-binding protein, and tumour necrosis factor receptor 1A predicted faster progression to clinically definite multiple sclerosis over 2 to 3 years.

Publication and source details

Original title: Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis

Caron Chapman; Robyn M Lucas; Anne-Louise Ponsonby; Bruce Taylor; Ausimmune Investigator Group ChapmanCaronDrCoulthardAlanProfDearKeithProfDwyerTerryProfKilpatrickTrevorProfLucasRobynProfMcMichaelTonyProfPenderMichaelProfPonsonbyAnne-LouiseProfTaylorBruceProfValeryPatricia CProfvan der MeiIngridA/ProfWilliamsDavidDr

Brain Communications · 2022

Correspondence to: Prof Robyn Lucas National Centre for Epidemiology and Population Health The Australian National University Canberra 2601, Australia E-mail: robyn.lucas@anu.edu.au

Caron Chapman and Robyn M Lucas joint first authors.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.2022https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. National Multiple Sclerosis Society of the United States of America10.13039/100000890 National Health and Medical Research Council of Australia10.13039/501100000925 NHMRC10.13039/501100000925 Multiple Sclerosis Research Australia10.13039/501100000924 Research Australia Fellowship, The Royal Australasian College of Physicians Cottrell Fellowship, a NHMRC Capacity Building (#224215

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T09:43:32.483302+00:00

DOI: 10.1093/braincomms/fcac181 · PMC9308470